19.51
price down icon1.22%   -0.24
pre-market  시장 영업 전:  19.10   -0.41   -2.10%
loading
전일 마감가:
$19.75
열려 있는:
$19.87
하루 거래량:
1.85M
Relative Volume:
0.40
시가총액:
$1.22B
수익:
$14.34M
순이익/손실:
$-199.00M
주가수익비율:
-4.977
EPS:
-3.92
순현금흐름:
$-183.51M
1주 성능:
-8.53%
1개월 성능:
-35.23%
6개월 성능:
+22.01%
1년 성능:
+29.55%
1일 변동 폭
Value
$19.34
$20.00
1주일 범위
Value
$19.34
$22.11
52주 변동 폭
Value
$7.76
$71.50

Uniqure N V Stock (QURE) Company Profile

Name
명칭
Uniqure N V
Name
전화
1-339-970-7000
Name
주소
PAASHEUVELWEG 25A, AMSTERDAM
Name
직원
209
Name
트위터
@uniQure_NV
Name
다음 수익 날짜
2025-10-31
Name
최신 SEC 제출 서류
Name
QURE's Discussions on Twitter

QURE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
QURE
Uniqure N V
19.51 1.23B 14.34M -199.00M -183.51M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Uniqure N V Stock (QURE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-11-04 다운그레이드 William Blair Outperform → Mkt Perform
2025-08-14 업그레이드 Mizuho Neutral → Outperform
2025-04-01 재개 Chardan Capital Markets Buy
2024-12-10 업그레이드 Raymond James Outperform → Strong Buy
2024-10-10 재개 Raymond James Outperform
2024-02-29 다운그레이드 Goldman Buy → Neutral
2023-12-19 다운그레이드 Mizuho Buy → Neutral
2022-03-17 업그레이드 UBS Neutral → Buy
2021-06-15 개시 BTIG Research Buy
2021-05-21 개시 UBS Neutral
2021-04-26 재개 Credit Suisse Outperform
2021-04-01 업그레이드 Mizuho Neutral → Buy
2021-01-07 업그레이드 Guggenheim Neutral → Buy
2020-11-24 개시 H.C. Wainwright Buy
2020-11-11 개시 Berenberg Buy
2020-11-09 개시 Jefferies Buy
2020-11-04 개시 Cantor Fitzgerald Overweight
2020-10-23 개시 RBC Capital Mkts Outperform
2020-08-25 개시 Raymond James Strong Buy
2020-07-31 업그레이드 Robert W. Baird Neutral → Outperform
2020-06-25 다운그레이드 Mizuho Buy → Neutral
2020-06-25 다운그레이드 Robert W. Baird Outperform → Neutral
2020-06-25 다운그레이드 Wells Fargo Overweight → Equal Weight
2019-12-03 개시 Cowen Outperform
2019-12-03 개시 Goldman Buy
2019-11-05 개시 Credit Suisse Outperform
2019-10-11 개시 Stifel Buy
2019-09-25 개시 Bernstein Outperform
2019-09-12 개시 Mizuho Buy
2019-07-30 다운그레이드 Guggenheim Buy → Neutral
2019-07-08 재확인 Cantor Fitzgerald Overweight
2019-04-12 개시 Piper Jaffray Overweight
2019-03-29 개시 Robert W. Baird Outperform
모두보기

Uniqure N V 주식(QURE)의 최신 뉴스

pulisher
Dec 14, 2025

QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.

Dec 14, 2025
pulisher
Dec 12, 2025

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire

Dec 12, 2025
pulisher
Dec 11, 2025

Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

Dec 11, 2025
pulisher
Dec 11, 2025

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire

Dec 11, 2025
pulisher
Dec 11, 2025

uniQure (NASDAQ:QURE) Price Target Lowered to $40.00 at Stifel Nicolaus - MarketBeat

Dec 11, 2025
pulisher
Dec 11, 2025

Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Dec 11, 2025
pulisher
Dec 11, 2025

uniQure (QURE) Price Target Lowered by Stifel Analyst | QURE Sto - GuruFocus

Dec 11, 2025
pulisher
Dec 10, 2025

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire

Dec 10, 2025
pulisher
Dec 10, 2025

Stempoint Capital LP Has $7.98 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat

Dec 10, 2025
pulisher
Dec 09, 2025

Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq

Dec 09, 2025
pulisher
Dec 09, 2025

Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus

Dec 09, 2025
pulisher
Dec 09, 2025

Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛

Dec 09, 2025
pulisher
Dec 09, 2025

Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat

Dec 09, 2025
pulisher
Dec 08, 2025

uniQure NV (HAM:UQ1) Non Operating Income : €-3.54 Mil (TTM As of Sep. 2025) - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

uniQure NV (HAM:UQ1) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

uniQure NV (HAM:UQ1) Total Long-Term Liabilities : €476.27 Mil (As of Sep. 2025) - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey

Dec 08, 2025
pulisher
Dec 08, 2025

uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

7 Hidden Multibagger Stocks to Invest In - Insider Monkey

Dec 07, 2025
pulisher
Dec 07, 2025

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years – Company AnnouncementFT.com - Financial Times

Dec 07, 2025
pulisher
Dec 06, 2025

Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ

Dec 06, 2025
pulisher
Dec 06, 2025

uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat

Dec 06, 2025
pulisher
Dec 05, 2025

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link

Dec 05, 2025
pulisher
Dec 05, 2025

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire

Dec 05, 2025
pulisher
Dec 05, 2025

uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st

Dec 05, 2025
pulisher
Dec 04, 2025

Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

Why uniQure Stock Is Trading Lower After FDA Meeting Update - Sahm

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure N.V. (QURE): A Bear Case Theory - Finviz

Dec 04, 2025
pulisher
Dec 04, 2025

UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus

Dec 04, 2025
pulisher
Dec 04, 2025

UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

Why Is UniQure Stock Falling In Pre-market? - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure Faces Setback in Gene Therapy Approval - TipRanks

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView — Track All Markets

Dec 04, 2025
pulisher
Dec 04, 2025

Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan

Dec 04, 2025
pulisher
Dec 04, 2025

uniQure N.V. $QURE Stake Reduced by Schroder Investment Management Group - MarketBeat

Dec 04, 2025

Uniqure N V (QURE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Uniqure N V 주식 (QURE) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Gut Robert
Director
Nov 06 '25
Sale
27.26
31,434
856,881
40,145
Kaye Jack
Director
Nov 04 '25
Option Exercise
9.88
38,810
383,535
38,249
Kaye Jack
Director
Nov 04 '25
Sale
30.34
38,810
1,177,517
20,439
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
자본화:     |  볼륨(24시간):